Elevate the value and credibility of your therapies with Ergomed’s Real World Evidence (RWE) solutions.
With experience in over 60 studies, access to diverse therapeutic databases, and a cross-functional team, Ergomed helps biotech and pharma companies showcase product safety and effectiveness in real-world settings, addressing essential benefit-risk questions beyond traditional trials.
Why Choose Ergomed for RWE Studies?
Our comprehensive RWE services offer specialized support for peri-approval programs, protocol design, and tailored operational strategies, especially in rare diseases, neurology, oncology, and more. We provide robust risk management, epidemiology insights, and dedicated health economics and market access support, ensuring your product’s full value is realized.
Case Study Highlight: Global PASS Registry Success
Through our work on a global PASS registry with 6,500+ enrolled patients across 15 countries, Ergomed demonstrated its expertise in capturing long-term safety data in real-world clinical settings.